Hudson Bay Capital Management LP Lowered Its Sarepta Therapeutics (SRPT) Position; Valeritas Holdings (VLRX) Shorts Down By 34.71%

December 11, 2017 - By Michael Collier

Hudson Bay Capital Management Lp decreased Sarepta Therapeutics Inc (SRPT) stake by 17% reported in 2017Q2 SEC filing. Hudson Bay Capital Management Lp sold 47,244 shares as Sarepta Therapeutics Inc (SRPT)’s stock rose 22.49%. The Hudson Bay Capital Management Lp holds 230,683 shares with $7.78 million value, down from 277,927 last quarter. Sarepta Therapeutics Inc now has $3.51B valuation. The stock increased 0.09% or $0.05 during the last trading session, reaching $54.31. About 420,251 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 96.82% since December 11, 2016 and is uptrending. It has outperformed by 80.12% the S&P500.

Valeritas Holdings Incorporated (NASDAQ:VLRX) had a decrease of 34.71% in short interest. VLRX’s SI was 15,800 shares in December as released by FINRA. Its down 34.71% from 24,200 shares previously. With 17,200 avg volume, 1 days are for Valeritas Holdings Incorporated (NASDAQ:VLRX)’s short sellers to cover VLRX’s short positions. The SI to Valeritas Holdings Incorporated’s float is 2.17%. The stock decreased 10.89% or $0.44 during the last trading session, reaching $3.6. About 4,690 shares traded. Valeritas Holdings, Inc. (NASDAQ:VLRX) has 0.00% since December 11, 2016 and is . It has underperformed by 16.70% the S&P500.

Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on developing technologies to treat patients with Type 2 diabetes. The company has market cap of $25.26 million. It offers V-Go, a disposable insulin delivery device for basal-bolus therapy. It currently has negative earnings. The firm also develops h-Patch, a controlled delivery technology platform; Mini-Ject, a disposable needle-free injection system that delivers drugs ranging from small molecules to large proteins, as well as antibodies and vaccines; and Micro-Trans microneedle array patch technology to deliver drugs into the dermis layer of the skin.

Among 27 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 20 have Buy rating, 1 Sell and 6 Hold. Therefore 74% are positive. Sarepta Therapeutics had 93 analyst reports since August 5, 2015 according to SRatingsIntel. J.P. Morgan maintained the shares of SRPT in report on Wednesday, September 6 with “Buy” rating. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Hold” rating given on Wednesday, August 26 by Cowen & Co. Needham maintained it with “Buy” rating and $55 target in Friday, October 2 report. RBC Capital Markets downgraded it to “Sector Perform” rating and $15.0 target in Tuesday, January 19 report. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, March 1. The company was upgraded on Monday, October 2 by Morgan Stanley. Needham maintained it with “Buy” rating and $75.0 target in Thursday, October 26 report. The firm has “Neutral” rating given on Tuesday, September 1 by SunTrust. As per Tuesday, December 20, the company rating was initiated by Goldman Sachs. RBC Capital Markets maintained the shares of SRPT in report on Monday, October 2 with “Buy” rating.

Hudson Bay Capital Management Lp increased Exxon Mobil Corp (Put) stake by 17,700 shares to 67,700 valued at $5.47M in 2017Q2. It also upped Danaher Corp Del (Call) stake by 3,900 shares and now owns 222,500 shares. Nuancemunications Inc (NASDAQ:NUAN) was raised too.

Investors sentiment increased to 2.88 in 2017 Q2. Its up 1.36, from 1.52 in 2017Q1. It improved, as 19 investors sold SRPT shares while 41 reduced holdings. 30 funds opened positions while 61 raised stakes. 41.29 million shares or 4.20% more from 39.62 million shares in 2017Q1 were reported. Manufacturers Life Insurance Com The holds 0% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 40,188 shares. Art Advsr Ltd Company invested in 141,300 shares. Us Bank & Trust De accumulated 2,624 shares. Canada Pension Plan Investment Board invested in 0% or 18,700 shares. Nuveen Asset Management Limited accumulated 31,815 shares or 0.01% of the stock. 399 are held by Hanson Mcclain Incorporated. Switzerland-based Jabre Cap Sa has invested 0.04% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Granite Point Capital Management Lp holds 0.53% or 63,220 shares. Fred Alger Management invested in 0.03% or 159,008 shares. Peddock Advsr invested in 54 shares or 0% of the stock. Eagle Asset Mgmt holds 0.16% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 798,412 shares. Sigma Planning Corporation holds 21,180 shares. Natl Bank Of America Corporation De stated it has 53,920 shares or 0% of all its holdings. Osterweis Mngmt has invested 0.29% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Point72 Asia (Hong Kong) Ltd has 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: